Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 9/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31408430 | 0.89 | MAPK1 (0.37) | MEN1KMT2AALK | |
| SCHEMBL31408279 | 0.88 | SMN1; SMN2 (0.36) | SUV39H2ALK | |
| SCHEMBL31408356 | 0.87 | POLB (0.39) | MEN1KMT2A | |
| SCHEMBL31408408 | 0.86 | SMN1; SMN2 (0.43) | SUV39H2 | |
| SCHEMBL31408514 | 0.84 | SMN1; SMN2 (0.36) | MEN1KMT2A | |
| SCHEMBL31408537 | 0.84 | SMN1; SMN2 (0.36) | JAK2JAK3PTK2MEN1KMT2A | |
| SCHEMBL31408437 | 0.83 | SMN1; SMN2 (0.34) | JAK2JAK3CCNT1 | |
| SCHEMBL31408327 | 0.83 | LRRK2 (0.35) | JAK2JAK3PTK2CCNT1 | |
| SCHEMBL31408237 | 0.83 | LRRK2 (0.35) | JAK2JAK3PTK2CCNT1 | |
| SCHEMBL31408404 | 0.83 | LRRK2 (0.36) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049604-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |